MZL facts

Question 1

gastric MALT % with HP

Answer 1

66%

Question 2

BM involvement in MALT

Answer 2

< 10%
no need for BMB

Question 3

MZL-IPI

Answer 3

MZL subtype (nodal or disseminated)
LDH
Cytopenias (Hb <12, Lymphocyte < 1000, Platelets <100 × 109/L)

Question 4

POD24 in MALT

Answer 4

inferior OS
increased risk of transformation

Question 5

MLT-IPI

Answer 5

age>70
LDH> ULN
Stage III/IV

Question 6

HP eradication in gastric MALT

Answer 6

70% CR

Question 7

Tests after eradication of HP

Answer 7

confirm eradication 6 weeks after Tx, and 2 weeks after PPI discontinuation
repeat endoscopy 3 mon after eradication

Question 8

Timing of endoscopic FU after eradication

Answer 8

not sooner than 3 months after eradication
then- every 3 mon for 12 months. define disease progression only after 12 months,

Question 9

pts predicted to not respond to eradication in gastric MALT

Answer 9

t(11:18)
HP negative
Tx with RT

Question 10

Tx of ocular MALT

Answer 10

Doxycycline 6 months- pulsatile
50-75% ORR

Question 11

RT dosage for ocular MALT

Answer 11

4 Gy
in order to reduce catarct

Question 12

ocular MALT pathogen

Answer 12

C. psittaci

Question 13

Bronchial MALT Tx

Answer 13

Surgical resection
RT for remaining lympoma
RX4 for no resectable tumors

Question 14

Dural EMZL

Answer 14

More common than DLBCL of dura
usually diagnosed after resection
Tx choice is RT if not already resected

Question 15

Colonic EMZL

Answer 15

rare
usually polypectomy is enough

Question 16

Thyroid EMZL

Answer 16

Rare
usually due to autoimmune thyroiditis
resection is possible

Question 17

Salivary gland EMZL

Answer 17

rare
due to sjogren
surgery is possible

Question 18

Primary cutaneous MZL

Answer 18

good prognosis
RT

Question 19

1st line Tx of advanced MZL

Answer 19

BR X 4

Question 20

R main in Adavnced MZL

Answer 20

Better PFS with no OS benefit
more toxicity

Question 21

nodal MZL %

Answer 21

10% of MZL

Question 22

Association of nodal MZL

Answer 22

HCV
eradication leads to lymphoma
regression in the majority of patients

Question 23

IgM paraprotein in nodal MZL %

Answer 23

10%
confuses with WM

Question 24

Mutation specific for NMZL

Answer 24

PTRPD

Question 25

SMZL %

Answer 25

20% of MZL

Question 26

Transformation of SMZL to DLBCL %

Answer 26

5-10%

Question 27

Tx of SMZL

Answer 27

R X4
BR

Question 28

2nd line Tx of NMZL

Answer 28

Zanu/Acala
Lenalidomide
Bi-specific Ab

Question 29

3rd line for NMZL

Answer 29

Bi-specific Ab
CART (ZUMA 5)

Question 30

2nd line for gastric MALT after eradication

Answer 30

RT